



Company Profile

RedHill Biopharma, established in 2009, is a publicly traded (NASDAQ / TASE: RDHL) specialty biopharmaceutical company, headquartered in Israel, primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases, including cancer.

RedHill's pipeline currently includes drugs in advanced clinical development stages addressing clear medical needs and aiming to relieve suffering and save lives. RedHill's drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development.


RedHill's products are based on several technology platforms and address several disease targets, thus providing for risk diversification.

RedHill's experienced management team, board of directors and advisory board, based in Israel, the US, Canada and Europe, comes with a successful track record of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise.

Stock Performance

NASDAQ: RDHL.US ¹

Last Trade:	9.05
Trade Time:	3:59 PM ET Sep 25, 2017
Change:	0.00 (0.000%)
Volume	88,556



TASE: RDHL ¹

Last Trade:	317.60
Trade Time:	4:24 PM IT Sep 25, 2017
Change:	-2.10 ↓ (0.657%)
Volume	385,685



Press Releases [\[View all \]](#)

Sep 18, 2017

[RedHill Biopharma Receives Notice of Allowance for a New U.S. Patent Covering its Combination Therapy for Hard-to-Treat Cancers](#)

Sep 18, 2017

[RedHill Biopharma to Present at the Cantor Fitzgerald Global Healthcare Conference](#)

Sep 13, 2017

[RedHill Biopharma Initiates Promotion of Esomeprazole Strontium Delayed-Release Capsules 49.3 mg in the U.S.](#)

Events [\[View all \]](#)

Sep 26–27, 2017

[BioPharm America 2017](#)

Oct 23–25, 2017

[BioNetwork Partnering Summit](#)

Financials [\[View all \]](#)

[Second Quarter Financial Results](#)

Feb 23, 2017

[Annual Report for Foreign Private Issuers \(20-F\)](#)

RedHill Biopharma Ltd

Investor Relations Department
21 Haarbaa St
Tel Aviv 64739
Israel

[Visit IR website](#)

[Sign-up for email alerts](#)

